Alvogen’s Norwich Pharmaceuticals division, along with Bausch Health, have jointly submitted appeals to the Federal Circuit seeking a rehearing on a case concerning the intellectual property rights of the drug, Xifaxan. Initial hearings of this issue resulted in the affirmation of a Delaware federal court’s decision to halt the production of a generic version of the drug until 2029. The implications of this case are significant, given Xifaxan’s status as a critical medication for the treatment of diarrhoea and certain brain diseases.
Included in the appeal is a strategic move by both Norwich Pharmaceuticals and Bausch Health, indicative of the central role Xifaxan plays in their pharmaceutical portfolios. The outcomes of this case could set an important precedent for how intellectual property rights are addressed within the rapidly evolving pharmaceutical industry.
Despite the complexities associated with these proceedings, they echo an industry-wide struggle between branded drug producers and generic drugmakers, both striving to control key elements of the pharmaceutical market, as demonstrated in this case. For additional information and developments on the story, kindly refer to the following Law360 article.